Anti-cancer drug clinical research
Abstract
Abstract Malignant tumors are major diseases that seriously threaten human health, and the unmet clinical demand for treatments in the field of oncology has been persistently large. The research and development of new antineoplastic drugs has become a powerful means to address this demand. The purpose of this guideline is to provide a systematic overview and summary of clinical research on antineoplastic drugs in terms of study format, trial staging, mechanism of action, ethical review, trial process, patient needs, and the evaluation of efficacy and adverse events. It provides practical suggestions and references to aid the fundamental role of clinical research on antineoplastic drugs, i.e., to address clinical needs and maximize patient benefits.
// Source
Authors: Fei Ma, Hongming Pan, Jian Li, Yanqiao Zhang, Hongyun Zhao, Jianping Xiong, Tianshu Liu, Jinfei Chen, Yi Ba, Chunxia Su, Yanhong Deng, Wenbin Li, Kangsheng Gu, Jianhua Chang, Xichun Hu, Yunpeng Liu, Jiayu Wang, Zhehai Wang, Jingxun Wu, Zhao Yan, Yongmei Yin, Qitao Yu, Dongsheng Zhang, Li Zhang, Binghe Xu, Lin Shen, Caicun Zhou
Institutions: Peking University, Zhongshan Hospital, Sun Yat-sen University, Chinese Academy of Medical Sciences & Peking Union Medical College, Peking Union Medical College Hospital, Harbin Medical University, Shanghai East Hospital, Sir Run Run Shaw Hospital, First Affiliated Hospital of Xiamen University, Sun Yat-sen University Cancer Center, Anhui Medical University, China Medical University, First Affiliated Hospital of Anhui Medical University, Shandong First Medical University, First Hospital of China Medical University, Sixth Affiliated Hospital of Sun Yat-sen University, Third Affiliated Hospital of Harbin Medical University, Shanghai Pulmonary Hospital, Fudan University Shanghai Cancer Center, Jiangsu Province Hospital, Shandong Tumor Hospital, Peking University Cancer Hospital, Nanchang University, First Affiliated Hospital of Nanchang University, Beijing Tian Tan Hospital, Tumor Hospital of Guangxi Medical University, Chinese Anti-Cancer Association